PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2414022-5	1985	Incubation of MCF-7 cells with 2.5 nM insulin for 48 h before exposure to 2 microM [3H]MTX for a further 24 h resulted in a significant increase in both total drug and total polyglutamates compared with control cells.	Polyglutamic Acid	174-188	insulin	Homo sapiens	38-45	
2414022-6	1985	Increasing the insulin concentration in the medium yielded further increases in polyglutamylation so that at 250 nM insulin and above total polyglutamates were increased by 64% compared with control cells.	Polyglutamic Acid	140-154	insulin	Homo sapiens	15-22	
2414022-7	1985	Further evaluation of the effects of physiologic insulin levels on polyglutamate synthesis revealed that 2.5 nM insulin caused an increase in the net glutamylation rate for each polyglutamate derivative during the final 12 h of a 24 h exposure to MTX.	Polyglutamic Acid	67-80	insulin	Homo sapiens	49-56	
2414022-7	1985	Further evaluation of the effects of physiologic insulin levels on polyglutamate synthesis revealed that 2.5 nM insulin caused an increase in the net glutamylation rate for each polyglutamate derivative during the final 12 h of a 24 h exposure to MTX.	Polyglutamic Acid	67-80	insulin	Homo sapiens	112-119	
2414022-7	1985	Further evaluation of the effects of physiologic insulin levels on polyglutamate synthesis revealed that 2.5 nM insulin caused an increase in the net glutamylation rate for each polyglutamate derivative during the final 12 h of a 24 h exposure to MTX.	Polyglutamic Acid	178-191	insulin	Homo sapiens	49-56	
2414022-7	1985	Further evaluation of the effects of physiologic insulin levels on polyglutamate synthesis revealed that 2.5 nM insulin caused an increase in the net glutamylation rate for each polyglutamate derivative during the final 12 h of a 24 h exposure to MTX.	Polyglutamic Acid	178-191	insulin	Homo sapiens	112-119	
2414022-8	1985	Analysis of the effects of insulin on polyglutamate binding to DHFR revealed that exposure to 2.5 nM insulin resulted in the preferential binding of higher polyglutamates to DHFR.	Polyglutamic Acid	38-51	insulin	Homo sapiens	27-34	
2414022-8	1985	Analysis of the effects of insulin on polyglutamate binding to DHFR revealed that exposure to 2.5 nM insulin resulted in the preferential binding of higher polyglutamates to DHFR.	Polyglutamic Acid	38-51	insulin	Homo sapiens	101-108	
2414022-8	1985	Analysis of the effects of insulin on polyglutamate binding to DHFR revealed that exposure to 2.5 nM insulin resulted in the preferential binding of higher polyglutamates to DHFR.	Polyglutamic Acid	156-170	insulin	Homo sapiens	27-34	
2414022-8	1985	Analysis of the effects of insulin on polyglutamate binding to DHFR revealed that exposure to 2.5 nM insulin resulted in the preferential binding of higher polyglutamates to DHFR.	Polyglutamic Acid	156-170	insulin	Homo sapiens	101-108	
2414022-9	1985	In MDA-231 cells, a breast cancer cell line with a poor capacity for polyglutamate synthesis, insulin exposure resulted in an increase in the cellular accumulation of each polyglutamate derivative, with the greatest proportionate increases occurring in the cellular levels of higher polyglutamates.	Polyglutamic Acid	69-82	insulin	Homo sapiens	94-101	
2414022-9	1985	In MDA-231 cells, a breast cancer cell line with a poor capacity for polyglutamate synthesis, insulin exposure resulted in an increase in the cellular accumulation of each polyglutamate derivative, with the greatest proportionate increases occurring in the cellular levels of higher polyglutamates.	Polyglutamic Acid	172-185	insulin	Homo sapiens	94-101	
2414022-9	1985	In MDA-231 cells, a breast cancer cell line with a poor capacity for polyglutamate synthesis, insulin exposure resulted in an increase in the cellular accumulation of each polyglutamate derivative, with the greatest proportionate increases occurring in the cellular levels of higher polyglutamates.	Polyglutamic Acid	283-297	insulin	Homo sapiens	94-101	
30815757-0	2019	Polyglutamic Acid Functionalization of Chitosan Nanoparticles Enhances the Therapeutic Efficacy of Insulin Following Oral Administration.	Polyglutamic Acid	0-17	insulin	Homo sapiens	99-106